Akoustis Technologies Inc reports results for the quarter ended in September - Earnings Summary

Aktis Oncology

14/11/2022 16:50

* Akoustis Technologies Inc  AKTS.OQ  reported a quarterly
adjusted loss of 28 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 20 cents per share.
    * Revenue rose 198% to $5.57 million from a year ago;
analysts
expected $5.56 million. 
    * Akoustis Technologies Inc's reported EPS for the quarter
was a
loss of 33 cents​.
    * The mean earnings estimate of analysts had fallen by
about 19.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Akoustis Technologies Inc shares had risen by 21.2% this
quarter and lost 46.1% so far this year.
    * The company reported a quarterly loss of $19.09 million.
    * Wall Street's median 12-month price target for Akoustis
Technologies Inc is $8.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 04:50 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.20          -0.28          Missed
 Jun. 30 2022      -0.19          -0.26          Missed
 Mar. 31 2022      -0.22          -0.22          Met
 Dec. 31 2021      -0.20          -0.23          Missed